Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Corporate Governance Announcements and Circulars Presentations Financial Report Investor Inquiry
Contact Us
SC TC EN
SC TC EN
Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Corporate Governance Announcements and Circulars Presentations Financial Report Investor Inquiry
Contact Us

News Center

News

EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial

EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial

EDP167 is an innovative siRNA therapeutic designed for the treatment of dyslipidemia, developed in line with one of the Company’s strategic focuses on cardiovascular diseases.

09.02.2026

Read More
EDDING Group and Genor Bio have completed the merger

EDDING Group and Genor Bio have completed the merger

Edding Genor Group founded.（stock code：06998.HK）

30.12.2025

Read More
EDDING Announces NMPA Approval Of VASCEPA® (Icosapent Ethyl) For New Cardiovascular Risk Reduction (CVRR) Indication in Mainland China

EDDING Announces NMPA Approval Of VASCEPA® (Icosapent Ethyl) For New Cardiovascular Risk Reduction (CVRR) Indication in Mainland China

EDDING have received regulatory approval for a new cardiovascular risk reduction (CVRR) indication of VASCEPA® (icosapent ethyl or IPE) from China’s National Medical Products Administration (NMPA).

05.07.2024

Read More
NMPA Accepts Marketing Application for VASCEPA® (icosapent ethyl) Cardiovascular Risk Reduction (CVRR) Indication

NMPA Accepts Marketing Application for VASCEPA® (icosapent ethyl) Cardiovascular Risk Reduction (CVRR) Indication

The new indication marketing application for the innovative cardiovascular drug VASCEPA® (icosapent ethyl) has been officially accepted by the National Medical Products Administration (NMPA).

15.11.2023

Read More
EDDING Recives Regulatroy Approval For MULPLETA® (Lusutrombopag Tablets) in Mainland China

EDDING Recives Regulatroy Approval For MULPLETA® (Lusutrombopag Tablets) in Mainland China

EDDING announced that NMPA has approved Mulpleta® (Lusutrombopag Tablets) for the adult patients with chronic liver disease accompany thrombocytopenia who are scheduled to undergo an operation procedure (including diagnostic procedure) (CLD) as an import drug.

29.06.2023

Read More
Latest Activities

09.02

EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial

2026

Read More

30.12

EDDING Group and Genor Bio have completed the merger

2025

Read More

05.07

EDDING Announces NMPA Approval Of VASCEPA® (Icosapent Ethyl) For New Cardiovascular Risk Reduction (CVRR) Indication in Mainland China

2024

Read More

15.11

NMPA Accepts Marketing Application for VASCEPA® (icosapent ethyl) Cardiovascular Risk Reduction (CVRR) Indication

2023

Read More

29.06

EDDING Recives Regulatroy Approval For MULPLETA® (Lusutrombopag Tablets) in Mainland China

2023

Read More

01.06

EDDING Receives Regulatory Approval For VASCEPA® (Icosapent Ethyl) in Mainland China

2023

Read More

16.01

Lusutrombopag Phase III Study Results in Mainland China was published on Hepatology International

2023

Read More
Technology Platforms
Product Center
About Us
Full Value Chain
News
Investor Relations
Contact Us

沪ICP备2021007464号

Copyright © 2025 design by EDDING

药监局备案号: (沪) -非经营性-2021-0038